Product Information
BEVESPI AEROSPHERE INHALER is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $40.8599 per GM under NDC 00310460012. Its NADAC has been published 498 times since Mar 22, 2017.
FDA first approved this application on Apr 25, 2016.
Strength
4.8; 9 ug/1; ug/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310460012
Classification
Brand
Dosage Form
AEROSOL, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FORMOTEROL FUMARATE; GLYCOPYRROLATEApproval Type
New Drug (NDA)
FDA Application
NDA208294FDA Approved
4/25/2016
On Market Since
10/3/2016
Pharmacological Classes
Price Statistics
The NADAC for BEVESPI AEROSPHERE INHALER has been published 498 times since Mar 22, 2017, and over the history we have for it it has risen 36.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $40.8599 per GM |
|---|---|
| All-time high | $40.9856 (May 13, 2026) |
| All-time low | $30.0343 (Mar 22, 2017) |
| 52-week high | $40.9856 |
| 52-week low | $39.7796 |
| Median price | $35.4750 |
| Average price | $35.7216 |
| Largest weekly change | +6.0% (Jan 10, 2018) |
| Weeks tracked | 498 |
| Tracking since | Mar 22, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Glycopyrrolate and formoterol fumarate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glycopyrrolate and formoterol fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BEVESPI AEROSPHERE INHALER?
The current National Average Drug Acquisition Cost (NADAC) for BEVESPI AEROSPHERE INHALER, manufactured by AstraZeneca Pharmaceuticals LP, is $40.8599 per GM (NDC 00310460012), effective Sep 30, 2026.
How has the price of BEVESPI AEROSPHERE INHALER changed over time?
Over the history we have for it, the NADAC for BEVESPI AEROSPHERE INHALER has risen 36.0%. It has been tracked across 498 weekly CMS publications since Mar 22, 2017.
What are the highest and lowest recorded NADAC prices for BEVESPI AEROSPHERE INHALER?
Since Mar 22, 2017, the NADAC for BEVESPI AEROSPHERE INHALER has ranged from a low of $30.0343 (Mar 22, 2017) to a high of $40.9856 (May 13, 2026), with a median of $35.4750 per GM.
Are there cheaper alternatives to BEVESPI AEROSPHERE INHALER?
No other NADAC-published product currently shares the active ingredient and strength of BEVESPI AEROSPHERE INHALER in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BEVESPI AEROSPHERE INHALER?
BEVESPI AEROSPHERE INHALER (NDC 00310460012) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.